TISSEEL (Fibrin Sealant)

HIGHLIGHTS OF PRESCRIBING INFORMATION

INDICATIONS AND USAGE

TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in surgical procedures to achieve hemostasis in the presence of uncontrollable bleeding from cuts, lacerations, or punctures that are bleeding profusely.

6.1 Overall Adverse Reactions

Anaphylactic and hypersensitivity reactions have been reported. No adverse events of this type were reported during the clinical trials. Exposure to solutions containing alcohol, iodine or heavy metals may cause TISSEEL to be denatured.

CONTRAINDICATIONS

Do not use the Sealer Protein Concentrate and Thrombin Solution in the event of a hypersensitivity reaction to the products or any component.

PRECAUTIONS

Patients who have had a prior allergic reaction to TISSEEL should be monitored carefully.

ADVERSE REACTIONS

Reactions are listed by body system and are divided into the following categories:

Uncommon

Hypersensitivity reactions

Other systemic reactions

TECHNICAL DETAILS

It is recommended that every time a sealed package is opened, the TISSEEL, and product must be used within 4 hours.

Table 1

<table>
<thead>
<tr>
<th>Dosage Form</th>
<th>Minimum size of the area to be covered</th>
<th>Maximum size of the area to be covered</th>
<th>Required package size of TISSEEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mL</td>
<td>40 cm²</td>
<td>80 cm²</td>
<td>1 or 2 packages</td>
</tr>
<tr>
<td>4 mL</td>
<td>80 cm²</td>
<td>160 cm²</td>
<td>1 package</td>
</tr>
<tr>
<td>8 mL</td>
<td>160 cm²</td>
<td>320 cm²</td>
<td>1 package</td>
</tr>
</tbody>
</table>

Table 1

<table>
<thead>
<tr>
<th>Dosage Form</th>
<th>Minimum size of the area to be covered</th>
<th>Maximum size of the area to be covered</th>
<th>Required package size of TISSEEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mL</td>
<td>40 cm²</td>
<td>80 cm²</td>
<td>1 or 2 packages</td>
</tr>
<tr>
<td>4 mL</td>
<td>80 cm²</td>
<td>160 cm²</td>
<td>1 package</td>
</tr>
<tr>
<td>8 mL</td>
<td>160 cm²</td>
<td>320 cm²</td>
<td>1 package</td>
</tr>
</tbody>
</table>

1. INSTRUCTIONS AND USAGE

2. DOSAGE AND ADMINISTRATION

3. DOSAGE FORMS AND STRENGTHS

4. RECOMMENDATIONS

5. ADVERSE REACTIONS

6. INDICATIONS AND USAGE

7. CONTRAINDICATIONS

8. PRECAUTIONS

9. ADVERSE REACTIONS

10. TECHNICAL DETAILS

11. INFORMATION FOR THE PHYSICIAN

12. INFORMATION FOR THE PATIENT

13. PATIENT COUNSELING INFORMATION

14. CLINICAL STUDIES

15. DRUG INTERACTIONS

16. CLINICAL PHARMACOLOGY

17. DOSAGE AND ADMINISTRATION

18. TECHNICAL DETAILS

19. PHARMACOLOGICAL, PHARMACODYNAMIC, AND PHARMACOTHERAPEUTIC INFORMATION

20. CONTRAINDICATIONS

21. RECOMMENDATIONS

22. ADVERSE REACTIONS

23. CLINICAL STUDIES

24. DRUG INTERACTIONS

25. CLINICAL PHARMACOLOGY

26. DOSAGE AND ADMINISTRATION

27. TECHNICAL DETAILS

28. PHARMACOLOGICAL, PHARMACODYNAMIC, AND PHARMACOTHERAPEUTIC INFORMATION

29. CONTRAINDICATIONS

30. RECOMMENDATIONS

31. ADVERSE REACTIONS

32. CLINICAL STUDIES

33. DRUG INTERACTIONS

34. CLINICAL PHARMACOLOGY

35. DOSAGE AND ADMINISTRATION

36. TECHNICAL DETAILS

37. PHARMACOLOGICAL, PHARMACODYNAMIC, AND PHARMACOTHERAPEUTIC INFORMATION

38. CONTRAINDICATIONS

39. RECOMMENDATIONS

40. ADVERSE REACTIONS

41. CLINICAL STUDIES

42. DRUG INTERACTIONS

43. CLINICAL PHARMACOLOGY

44. DOSAGE AND ADMINISTRATION

45. TECHNICAL DETAILS

46. PHARMACOLOGICAL, PHARMACODYNAMIC, AND PHARMACOTHERAPEUTIC INFORMATION

47. CONTRAINDICATIONS

48. RECOMMENDATIONS

49. ADVERSE REACTIONS

50. CLINICAL STUDIES

51. DRUG INTERACTIONS

52. CLINICAL PHARMACOLOGY

53. DOSAGE AND ADMINISTRATION

54. TECHNICAL DETAILS

55. PHARMACOLOGICAL, PHARMACODYNAMIC, AND PHARMACOTHERAPEUTIC INFORMATION

56. CONTRAINDICATIONS

57. RECOMMENDATIONS

58. ADVERSE REACTIONS

59. CLINICAL STUDIES

60. DRUG INTERACTIONS

61. CLINICAL PHARMACOLOGY

62. DOSAGE AND ADMINISTRATION

63. TECHNICAL DETAILS

64. PHARMACOLOGICAL, PHARMACODYNAMIC, AND PHARMACOTHERAPEUTIC INFORMATION

65. CONTRAINDICATIONS

66. RECOMMENDATIONS

67. ADVERSE REACTIONS

68. CLINICAL STUDIES

69. DRUG INTERACTIONS

70. CLINICAL PHARMACOLOGY

71. DOSAGE AND ADMINISTRATION

72. TECHNICAL DETAILS

73. PHARMACOLOGICAL, PHARMACODYNAMIC, AND PHARMACOTHERAPEUTIC INFORMATION
1. INSTRUCTIONS AND USAGE

2. INSTRUCTIONS AND USAGE

3. Method of Application

4. Contraindications

5. Dosage and Administration

6.2 Clinical Trials Experience

7. Interactions

8. Use in Specific Populations

9. Other Ingredients contain human albumin, reducing clot and fibrin formation (2.2).

10. Aprotinin Hypersensitivity (4.2).

11. Do not use TISSEEL in individuals with a known hypersensitivity to aprotinin.

12. Do not use TISSEEL in individuals with a known hypersensitivity to heparin.

13. Safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

14. Safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

15. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

16. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

17. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

18. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

19. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

20. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

21. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

22. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

23. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

24. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.

25. The safety and effectiveness of the combined use of TISSEEL with other biocompatible materials has not been established.
HIV-1: n.d. = not determined
spiked with stock virus suspensions of known titers followed by further processing under conditions equivalent to
from manufacturing intermediates for each of the two human plasma derived components. These samples were
viral transmission. In particular, vapor heating and solvent/detergent treatment processes are included in the
The manufacturing procedure for TISSEEL includes processing steps designed to further reduce the risk of
distribution to other organs or tissues is not expected.
of fibrin. Free Aprotinin and its metabolites have a half-life of 30 to 60 minutes and are eliminated by the kidney.
ion Exchange Chromatography n.d. n.d. n.d. n.d. 3.6
Solvent/Detergent Treatment > 5.3 n.d. > 5.5 > 6.4 n.d.
Overall Reduction Factor (ORF) >10.8 > 5.6 >11.4 >12.6 3.9
Sealer Protein Component
Thrombin Component

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

11 DESCRIPTION
TISSEEL (Fibrin Sealant) is a two-compartment single-use syringe. Each compartment contains 4 mL of the
solution with calcium chloride to activate prothrombin to thrombin. The solution subsequently undergoes
Thrombin (Human) is provided as a liquid solution for reconstitution with a vial containing calcium chloride for
Thrombin (Human) is a sterile, non-pyrogenic, vapor-heated and solvent/detergent treated preparation made from

8.5 Geriatric Use

Table 3

Table 5

Table 2

Table 4

Table 1

12 CLINICAL PHARMACOLOGY
10.9b Distribution

8.4 Pediatric Use

8.3 Nursing Mothers

Table 6

14 CLINICAL STUDIES

14.1 Cardiac Surgery

The manufacturing procedure for TISSEEL includes steps designed to further reduce the risk of
expression is present in all layers of the surgical wound to effectively seal small leaks and reduce bleeding.

9.5 Precautions

13.14 Photostability

12.12 Animal Studies

12.3 Carcinogenesis, Mutagenesis, Impairment of Fertility

13.11 Irritancy

13.9b Carcinogenesis, Mutagenesis, Impairment of Fertility

12.12 Animal Studies

17.12.10   10:57